Reliability and validity of the Cystic Fibrosis Questionnaire-Revised for children and parents in Turkey: Cross-sectional study


YÜKSEL H., YILMAZ Ö., DOĞRU ERSÖZ D., KARADAĞ B. T., Unal F., Quittner A. L.

Quality of Life Research, cilt.22, sa.2, ss.409-414, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s11136-012-0152-4
  • Dergi Adı: Quality of Life Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
  • Sayfa Sayıları: ss.409-414
  • Anahtar Kelimeler: Cystic Fibrosis Questionnaire-Revised, Cystic fibrosis, Validity, Reliability
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Purpose: The purpose of study was to translate Cystic Fibrosis Questionnaire-Revised (CFQ-R) into Turkish for children with cystic fibrosis (CF) and evaluate its reliability and validity. This is the first CF-specific health-related quality of life (HRQOL) measure validated in a Muslim country. Methods: Fifty-one children aged 6-13 years treated at four centers in Turkey and 30 parents participated in this cross-sectional study. Demographic characteristics and disease severity parameters were recorded for all participants. All participants completed the parent or child versions of CFQ-R and KINDL questionnaires at enrollment. Reliability and construct validity analysis were carried out. Results: Both children and parents endorsed a range of responses, with no evidence of floor or ceiling effects. Item-to-total correlations indicated that most items were more highly correlated with their intended scale than competing scales. Good internal consistency was found for majority of child and parent scales. CFQ-R scales correlated significantly with clinical indices of disease severity. Good evidence of convergent validity with a generic HRQOL scale was found. Conclusion: Turkish versions of CFQ-R Child and Parent instruments have demonstrated adequate reliability and validity and can be utilized in clinical trials or integrated into clinical evaluation and follow-up of Turkish children with CF. © 2012 Springer Science+Business Media B.V.